Congratulations to the first authors, Alexander Boucher & Courtney Anderson, Michal Guberman & Guy Biber, for leading robust methodologies providing elegant demonstrations for each mode of action and many thanks to the whole scientific & management teams for support with these manuscripts💥✨10/10

Eliciting multi-modal, anti-malignancy functions may be required to achieve long-term remissions. Together, these manuscripts provide a foundation for the development engineered B cells as novel polymorphic therapeutics 9/10
www.frontiersin.org/journals/imm...
www.frontiersin.org/journals/imm...

Specifically, we highlight B cell-mediated, antigen-induced activation of T cells both by direct uptake for presentation on MHC, and by immune complexes formed by antibody-antigen pairs acquired by dendritic cells 8/10

In Guberman & Biber et al., we demonstrate that mouse engineered B cells targeting intracellular tumor antigens activate polyclonal antigen-specific T cells, including cytotoxic T cells 7/10
www.frontiersin.org/journals/imm...

Uniquely, we show that engineered B cells may acquire antigens from tumor cell membranes for presentation to T cells and that antibodies secreted by differentiated engineered B cells induce cytotoxic reactions 6/10

In Boucher & Anderson et al., we demonstrate that human engineered B cells targeting tumor-associated antigens enable antibody-mediated functions 5/10
www.frontiersin.org/journals/imm...

Employing a creative engineering approach, we leverage both isoforms simultaneously to harness a multi-modal therapeutic platform 4/10

When released as a secreted protein, antibodies enable cytotoxic functions as well as immune-complex-mediated antigen presentation following uptake by other antigen-presenting cells 3/10

B(eautiful) cells are antigen-specific-presenting cells. While coded as a receptor, the antibodies they express enable high-affinity internalization of antigens for presentations on MHC molecules to activate T cells 2/10